Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CLINIMIX E 4.25/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER vs AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
CLINIMIX E is a parenteral nutrition solution providing amino acids, electrolytes, and dextrose for intravenous infusion. It supplies essential and non-essential amino acids for protein synthesis, dextrose as a caloric source, and electrolytes for maintenance of acid-base balance and cellular function. Calcium is included for bone health and neuromuscular function.
Provides essential amino acids and histidine for protein synthesis in patients unable to tolerate oral or enteral nutrition, supporting nitrogen balance and tissue repair. The amino acids are utilized for anabolic processes and metabolic pathways.
Parenteral nutrition for patients requiring intravenous feeding when oral or enteral nutrition is not possible, insufficient, or contraindicated.,Adjunct to other nutritional support in conditions such as gastrointestinal tract obstruction, malabsorption, preoperative bowel rest, or severe catabolic states.
Treatment of uremic patients undergoing dialysis who require essential amino acid supplementation,Nutritional support in patients with renal insufficiency or failure where nonessential nitrogen sources are contraindicated
Administer intravenously. Dose is individualized based on patient's metabolic requirements, clinical condition, and tolerance. Typical adult dose: 500-2000 m L per day, infused at a rate not exceeding 2-3 m L/kg/hour (or 2 mg/kg/min of amino acids), equivalent to 1-1.5 g/kg/day of amino acids and 3-7 g/kg/day of dextrose.
Intravenous infusion: 500 m L of 5.2% solution (26 g amino acids) over 8-12 hours daily, providing 0.8-1.2 g/kg/day of amino acids depending on metabolic needs.
Not applicable as a single entity; components have variable half-lives: dextrose ~1-2h, amino acids ~1-3h for distribution, electrolytes vary. No terminal half-life defined.
Approximately 2-4 hours for most essential amino acids; clinical context: rapid clearance necessitates continuous infusion for stable plasma levels.
Amino acids are metabolized via transamination and deamination pathways; dextrose is metabolized via glycolysis and the citric acid cycle; electrolytes are not metabolized but are utilized in physiological processes.
Amino acids are metabolized via transamination, deamination, and incorporation into proteins. Hepatic and renal pathways involved in nitrogen disposal and urea cycle.
Excretion depends on amino acid and electrolyte composition; nitrogen waste is eliminated renally as urea. Calcium and magnesium are primarily renally excreted; potassium is mostly renally eliminated. Dextrose is metabolized to CO2 and water. In renal impairment, accumulation may occur.
Renal: >95% as amino acids and metabolites; negligible biliary/fecal.
Low for amino acids and electrolytes; calcium ~40% bound to albumin, magnesium ~30% bound, potassium not protein-bound.
Minimal (<10%) for most amino acids; not significantly protein-bound.
Not defined as a composite; amino acids distribute into total body water (0.5-0.6 L/kg), calcium distributes into extracellular fluid (~0.2 L/kg), potassium intracellularly (~4 L/kg).
Approximately 0.2-0.4 L/kg total body water; reflects distribution primarily into extracellular fluid.
100% (intravenous administration).
Intravenous: 100%.
Contraindicated in severe renal failure (e GFR < 30 m L/min/1.73 m²) without renal replacement therapy; if used, reduce dose by 50% for moderate impairment (e GFR 30-59 m L/min/1.73 m²) and monitor electrolytes.
For GFR < 30 m L/min: reduce dose to 0.5-0.8 g/kg/day; for GFR < 15 m L/min: 0.3-0.5 g/kg/day; avoid if severe untreated uremia.
Contraindicated in severe hepatic impairment (Child-Pugh class C); use with caution in Child-Pugh class B (reduce amino acid dose by 50-75%); no adjustment for Child-Pugh class A.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25-50%; Child-Pugh C: contraindicated due to risk of hepatic encephalopathy.
Dose based on body weight: Amino acids: 1-3 g/kg/day; Dextrose: 5-20 g/kg/day. Initiate at lower end and increase gradually. Typical infusion rate: 1-2 m L/kg/hour, titrate to blood glucose and metabolic tolerance. Not recommended for neonates without risk-benefit assessment.
Infants and children: 1-2 g/kg/day as continuous infusion; neonates: 0.5-1 g/kg/day, titrated to metabolic response.
No specific dose adjustment, but use with caution due to potential age-related decline in renal function. Monitor fluid balance and renal function; start at lower doses (e.g., 500 m L/day) and adjust based on tolerance and clinical response.
Start at 0.6-0.8 g/kg/day; monitor renal function and protein tolerance; adjust for comorbidities like renal impairment or heart failure.
Not applicable. CLINIMIX E does not carry an FDA black box warning.
Not for intravenous infusion. For oral or enteral use only. Do not administer parenterally.
Risk of infection due to catheter-related bloodstream infections; strict aseptic technique required.,Metabolic complications including hyperglycemia, hypoglycemia, electrolyte imbalances, and acid-base disturbances.,Hepatic and renal function monitoring required; adjust infusion rates accordingly.,Aluminum toxicity risk in patients with renal impairment; prolonged use may lead to bone disease.,Do not administer simultaneously with blood products through the same infusion line.
Monitor serum electrolytes, BUN, and ammonia levels; risk of hyperammonemia in hepatic impairment,Use with caution in patients with metabolic acidosis or fluid overload,May cause gastrointestinal intolerance; adjust rate of administration
Hypersensitivity to any component of the solution.,Severe electrolyte disturbances or metabolic acidosis.,Anuria or severe renal impairment (unless dialyzed adequately).,Hepatic coma or severe hepatic insufficiency.,Uncorrected hyperglycemia or hyperosmolar coma.
Hypersensitivity to any component,Phenylketonuria (contains phenylalanine),Severe hepatic failure with hyperammonemia
None; this is an intravenous solution providing nutrition. Do not consume oral nutrients without clinical guidance as it may interfere with nutritional balance.
No specific food interactions. Patients should follow prescribed dietary protein restrictions if indicated (e.g., in hepatic encephalopathy). Avoid alcohol as it may worsen liver function.
CLINIMIX E 4.25/5 contains amino acids, dextrose, and electrolytes, including calcium. No teratogenic effects have been reported in animal or human studies with standard components at physiological concentrations. However, calcium administration in the third trimester may be associated with neonatal hypocalcemia if maternal hypercalcemia occurs. No specific fetal risks are identified for the first two trimesters when used as indicated for parenteral nutrition.
Amino acid solutions like Aminess 5.2% are essential for fetal development. No teratogenic effects reported; however, use only if clearly needed as maternal nutritional status directly impacts fetal outcomes.
Safety in breastfeeding is not established. Components excrete into milk in low amounts; no specific M/P ratio available. Parenteral nutrition use in lactating women should be with caution. Monitor infant for electrolyte imbalance.
No data available on milk concentrations. Essential amino acids are normal components of breast milk. Use with caution; benefits likely outweigh risks in malnourished mothers.
Pregnancy may increase fluid and electrolyte requirements. Glucose monitoring is essential as gestational diabetes may develop. Calcium dosing may need adjustment to avoid hypercalcemia. No specific dose changes for amino acids; follow standard parenteral nutrition guidelines. Adjust infusion rate based on clinical status and avoid iatrogenic hyperglycemia.
Pregnancy increases plasma volume and glomerular filtration rate, potentially altering pharmacokinetics. Monitor clinical response and consider dose adjustments based on metabolic demands; no specific dose adjustment guidelines available.
This is a premixed parenteral nutrition solution containing amino acids, dextrose, electrolytes, and calcium. Do not add other medications or supplements without compatibility verification. Monitor serum electrolytes, glucose, and calcium levels regularly. Use inline filter; do not administer if precipitate is present. Contains sulfite-free formulation; safe for sulfite-sensitive patients.
Monitor serum ammonia levels in patients with hepatic impairment as essential amino acids may exacerbate hyperammonemia. Use with caution in fluid-restricted patients due to high volume load. Ensure adequate non-protein calories to promote protein synthesis and prevent amino acid catabolism. Do not administer simultaneously with blood products via same IV line.
This medication is given through a vein; do not stop or adjust the infusion rate on your own.,Report any signs of infection at the IV site (redness, swelling, pain) or allergic reactions (rash, difficulty breathing).,This solution provides complete nutrition; do not eat or drink without your doctor's approval.,Notify your doctor if you experience nausea, vomiting, headache, or unusual tiredness.
This solution provides essential amino acids to support protein synthesis when you cannot eat enough protein.,It is given intravenously; report any burning, pain, or swelling at the IV site.,Your blood may be monitored for ammonia and electrolyte levels during treatment.,Inform your healthcare provider if you have liver disease, diabetes, or fluid restrictions.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CLINIMIX E 4.25/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER vs AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE, answered by our medical review team.
CLINIMIX E 4.25/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER is a Parenteral Nutrition Solution that works by CLINIMIX E is a parenteral nutrition solution providing amino acids, electrolytes, and dextrose for intravenous infusion. It supplies essential and non-essential amino acids for protein synthesis, dextrose as a caloric source, and electrolytes for maintenance of acid-base balance and cellular function. Calcium is included for bone health and neuromuscular function.. AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE is a Parenteral Nutrition Solution that works by Provides essential amino acids and histidine for protein synthesis in patients unable to tolerate oral or enteral nutrition, supporting nitrogen balance and tissue repair. The amino acids are utilized for anabolic processes and metabolic pathways.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CLINIMIX E 4.25/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER and AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE depend on the specific clinical indication. These are both Parenteral Nutrition Solution agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CLINIMIX E 4.25/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER is: Administer intravenously. Dose is individualized based on patient's metabolic requirements, clinical condition, and tolerance. Typical adult dose: 500-2000 m L per day, infused at a rate not exceeding 2-3 m L/kg/hour (or 2 mg/kg/min of amino acids), equivalent to 1-1.5 g/kg/day of amino acids and 3-7 g/kg/day of dextrose.. The standard adult dose of AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE is: Intravenous infusion: 500 m L of 5.2% solution (26 g amino acids) over 8-12 hours daily, providing 0.8-1.2 g/kg/day of amino acids depending on metabolic needs.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CLINIMIX E 4.25/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER and AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CLINIMIX E 4.25/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER is classified as Category C. CLINIMIX E 4.25/5 contains amino acids, dextrose, and electrolytes, including calcium. No teratogenic effects have been reported in animal or human studies with standard components. AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE is classified as Category C. Amino acid solutions like Aminess 5.2% are essential for fetal development. No teratogenic effects reported; however, use only if clearly needed as maternal nutritional status dire. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.